Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Oct 3;13:951817. doi: 10.3389/fimmu.2022.951817

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Zhong, Yin, Chen, Xie, Lv, Yang, Yang, Zhou, Wang, Zhong, Gao, Zhou, Chen, Tu, Liao, Zhang, Zhang, Lu, Zheng, Zhang, Wu and Zhang

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

PFS and OS of PLELC treated patients with ICI monotherapy or combination therapy. (A, B) Progression-free survival (PFS; blue bar) and overall survival (OS; orange bar) (in months) in PLELC patients who underwent treatment with ICI monotherapy or combination therapy at the initiation of first immunotherapy. Best responses during the ICI treatment are shown on the y-axis. First line: first-line treatment with ICI monotherapy or combination therapy. Second line: second- or more line treatment with ICI monotherapy or combination therapy. PR, partial response; SD, stable disease; PD, progression disease. Patients with green arrows were undergoing ICI treatment at the last follow-up. Patients with blue arrows were alive at the last follow-up. *: ICI progression.